Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Post hoc analyses of surrogate markers of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis in patients with type 2 diabetes in a digitally supported continuous care intervention: an open-label, non-randomised controlled study.

Vilar-Gomez E, Athinarayanan SJ, Adams RN, Hallberg SJ, Bhanpuri NH, McKenzie AL, Campbell WW, McCarter JP, Phinney SD, Volek JS, Chalasani N.

BMJ Open. 2019 Feb 25;9(2):e023597. doi: 10.1136/bmjopen-2018-023597.

2.

Improvement in patient-reported sleep in type 2 diabetes and prediabetes participants receiving a continuous care intervention with nutritional ketosis.

Siegmann MJ, Athinarayanan SJ, Hallberg SJ, McKenzie AL, Bhanpuri NH, Campbell WW, McCarter JP, Phinney SD, Volek JS, Van Dort CJ.

Sleep Med. 2019 Mar;55:92-99. doi: 10.1016/j.sleep.2018.12.014. Epub 2019 Jan 3.

3.

Transcriptional regulation of PNPLA3 and its impact on susceptibility to nonalcoholic fatty liver Disease (NAFLD) in humans.

Liu W, Anstee QM, Wang X, Gawrieh S, Gamazon ER, Athinarayanan S, Liu YL, Darlay R, Cordell HJ, Daly AK, Day CP, Chalasani N.

Aging (Albany NY). 2016 Oct 13;9(1):26-40. doi: 10.18632/aging.101067.

4.

Fatty acid desaturase 1 gene polymorphisms control human hepatic lipid composition.

Wang L, Athinarayanan S, Jiang G, Chalasani N, Zhang M, Liu W.

Hepatology. 2015 Jan;61(1):119-28. doi: 10.1002/hep.27373. Epub 2014 Dec 15.

5.

Genetic polymorphism of cytochrome P450 4F2, vitamin E level and histological response in adults and children with nonalcoholic fatty liver disease who participated in PIVENS and TONIC clinical trials.

Athinarayanan S, Wei R, Zhang M, Bai S, Traber MG, Yates K, Cummings OW, Molleston J, Liu W, Chalasani N.

PLoS One. 2014 Apr 23;9(4):e95366. doi: 10.1371/journal.pone.0095366. eCollection 2014.

6.

Supplemental Content

Loading ...
Support Center